545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)

• Celeste Lebbe,
• Shailender Bhatia,
• Melissa Burgess,
• Jean-Jaques Grob,
• Sadhna Shankar,
• Giovanni Grignani,
• Piotr Rutkowski,
• Michele Guida,
• Chuan Tian,
• Natalie Prinzi,
• Enrica Teresa Tanda,
• Jennifer Pulini

Affiliations

Celeste Lebbe

AP-HP Dermatology and CIC, INSERM U976, Saint Louis Hospital, Université de Paris, Paris, France

Shailender Bhatia

University of Washington / Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Melissa Burgess

Aff179 grid.478063.e0000000404569819University of Pittsburgh Cancer Institute Pittsburgh PA USA

Jean-Jaques Grob

Aff2 grid.5399.60000000121764817Aix-Marseille University, Hopital de la Timone Marseille France

Sadhna Shankar

Aff177 grid.421076.60000000404326278MacroGenics, Inc. Rockville MD USA

Giovanni Grignani

Division of Medical Oncology, Candiolo Cancer Institute - FPO, IRCCS, Torino, Italy

Piotr Rutkowski

Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute of Oncology Warsaw, Warszawa, Poland

Michele Guida

Rare tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy

Chuan Tian

Incyte Corporation, Wilmington, DE, USA

Natalie Prinzi

Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

Enrica Teresa Tanda

6IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genoa, Italy

Jennifer Pulini

9Incyte Corporation, Ambler, USA